Ionis Pharmaceuticals, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Ionis Pharmaceuticals, Inc. (IONS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $45.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $45.59M, a 50.98% increase year-over-year.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $43.29M, a 43.31% increase year-over-year.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $43.67M, a 19.85% increase year-over-year.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $31.58M, a 2.80% decline year-over-year.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $135.66M, a 3.56% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $131.00M, a 23.81% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $105.81M, a 5.53% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $100.26M, a 16.92% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.59M 10-Q · filed 2026-07-29 | $88.89M 10-Q · filed 2026-07-29 | $132.56M derived: sum of 3 quarters · filed 2026-07-29 | $164.14M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $43.29M 10-Q · filed 2026-04-29 | $86.97M derived: sum of 2 quarters · filed 2026-04-29 | $118.55M derived: sum of 3 quarters · filed 2026-04-29 | $148.75M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $43.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.26M derived: sum of 2 quarters · filed 2026-02-26 | $105.45M derived: sum of 3 quarters · filed 2026-07-29 | $135.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.58M 10-Q · filed 2025-10-29 | $61.78M derived: sum of 2 quarters · filed 2026-07-29 | $91.99M 10-Q · filed 2025-10-29 | $128.43M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $30.20M 10-Q · filed 2026-07-29 | $60.41M 10-Q · filed 2026-07-29 | $96.85M derived: sum of 3 quarters · filed 2026-07-29 | $129.34M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $30.21M 10-Q · filed 2026-04-29 | $66.65M derived: sum of 2 quarters · filed 2026-04-29 | $99.14M derived: sum of 3 quarters · filed 2026-04-29 | $129.87M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $36.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.93M derived: sum of 2 quarters · filed 2026-02-26 | $99.66M derived: sum of 3 quarters · filed 2026-02-26 | $131.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.49M 10-Q · filed 2025-10-29 | $63.22M derived: sum of 2 quarters · filed 2025-10-29 | $94.56M 10-Q · filed 2025-10-29 | $120.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.73M 10-Q · filed 2025-07-30 | $62.07M 10-Q · filed 2025-07-30 | $88.40M derived: sum of 3 quarters · filed 2026-02-26 | $114.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $31.34M 10-Q · filed 2025-04-30 | $57.68M derived: sum of 2 quarters · filed 2026-02-26 | $83.64M derived: sum of 3 quarters · filed 2026-02-26 | $110.20M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $26.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.30M derived: sum of 2 quarters · filed 2026-02-26 | $78.86M derived: sum of 3 quarters · filed 2026-02-26 | $105.81M 10-K · filed 2026-02-26 |
| 2023-09-30 | $25.96M 10-Q · filed 2024-11-06 | $52.52M derived: sum of 2 quarters · filed 2024-11-06 | $79.47M 10-Q · filed 2024-11-06 | $105.16M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-06-30 | $26.56M 10-Q · filed 2024-08-01 | $53.51M 10-Q · filed 2024-08-01 | $79.20M derived: sum of 3 quarters · filed 2025-02-19 | $103.03M derived: sum of 4 quarters · filed 2025-02-19 |
| 2023-03-31 | $26.95M 10-Q · filed 2024-05-07 | $52.64M derived: sum of 2 quarters · filed 2025-02-19 | $76.47M derived: sum of 3 quarters · filed 2025-02-19 | $100.98M derived: sum of 4 quarters · filed 2025-02-19 |
| 2022-12-31 | $25.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $49.53M derived: sum of 2 quarters · filed 2025-02-19 | $74.03M derived: sum of 3 quarters · filed 2025-02-19 | $100.26M 10-K · filed 2025-02-19 |
| 2022-09-30 | $23.84M 10-Q · filed 2023-11-02 | $48.34M derived: sum of 2 quarters · filed 2023-11-02 | $74.58M 10-Q · filed 2023-11-02 | $96.83M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $24.50M 10-Q · filed 2023-08-09 | $50.74M 10-Q · filed 2023-08-09 | $73.00M derived: sum of 3 quarters · filed 2024-02-21 | $103.53M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $26.24M 10-Q · filed 2023-05-03 | $48.49M derived: sum of 2 quarters · filed 2024-02-21 | $79.03M derived: sum of 3 quarters · filed 2024-02-21 | $109.05M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $22.26M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $52.80M derived: sum of 2 quarters · filed 2024-02-21 | $82.82M derived: sum of 3 quarters · filed 2024-02-21 | $120.68M 10-K · filed 2024-02-21 |
| 2021-09-30 | $30.54M 10-Q · filed 2022-11-09 | $60.56M derived: sum of 2 quarters · filed 2022-11-09 | $98.42M 10-Q · filed 2022-11-09 | $193.46M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-06-30 | $30.02M 10-Q · filed 2022-08-09 | $67.88M 10-Q · filed 2022-08-09 | $162.92M derived: sum of 3 quarters · filed 2023-02-22 | $208.77M derived: sum of 4 quarters · filed 2023-02-22 |
| 2021-03-31 | $37.86M 10-Q · filed 2022-05-04 | $132.90M derived: sum of 2 quarters · filed 2023-02-22 | $178.75M derived: sum of 3 quarters · filed 2023-02-22 | $227.19M derived: sum of 4 quarters · filed 2023-02-22 |
| 2020-12-31 | $95.04M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $140.88M derived: sum of 2 quarters · filed 2023-02-22 | $189.33M derived: sum of 3 quarters · filed 2023-02-22 | $230.12M 10-K · filed 2023-02-22 |
| 2020-09-30 | $45.84M 10-Q · filed 2021-11-03 | $94.29M derived: sum of 2 quarters · filed 2021-11-03 | $135.08M 10-Q · filed 2021-11-03 | $170.09M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $48.44M 10-Q · filed 2021-08-04 | $89.23M 10-Q · filed 2021-08-04 | $124.24M derived: sum of 3 quarters · filed 2022-02-25 | $148.37M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $40.79M 10-Q · filed 2021-05-05 | $75.80M derived: sum of 2 quarters · filed 2022-02-25 | $99.93M derived: sum of 3 quarters · filed 2022-02-25 | $141.86M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $35.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $59.14M derived: sum of 2 quarters · filed 2022-02-25 | $101.07M derived: sum of 3 quarters · filed 2022-02-25 | $146.57M 10-K · filed 2022-02-25 |
| 2019-09-30 | $24.13M 10-Q · filed 2020-11-04 | $66.06M derived: sum of 2 quarters · filed 2020-11-04 | $111.56M 10-Q · filed 2020-11-04 | $145.67M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $41.93M 10-Q · filed 2020-08-05 | $87.44M 10-Q · filed 2020-08-05 | $121.54M derived: sum of 3 quarters · filed 2021-02-24 | $156.42M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $45.51M 10-Q · filed 2020-05-06 | $79.61M derived: sum of 2 quarters · filed 2021-02-24 | $114.49M derived: sum of 3 quarters · filed 2021-02-24 | $148.37M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $34.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $68.98M derived: sum of 2 quarters · filed 2021-02-24 | $102.86M derived: sum of 3 quarters · filed 2021-02-24 | $131.31M 10-K · filed 2021-02-24 |
| 2018-09-30 | $34.88M 10-Q · filed 2019-11-06 | $68.76M derived: sum of 2 quarters · filed 2019-11-06 | $97.21M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $33.88M 10-Q · filed 2019-08-08 | $62.33M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $28.45M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | $85.97M 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $72.11M 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $59.31M 10-K · filed 2018-02-28 | |||
| 2014-12-31 | $31.38M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $11.42M 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $8.57M 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $9.85M 10-K · filed 2014-03-03 | |||
| 2010-12-31 | $12.16M 10-K · filed 2013-02-28 | |||
| 2009-12-31 | $11.83M 10-K · filed 2012-02-29 | |||
| 2008-12-31 | $15.06M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |